Search Results - "Fontana, Raffaele"
-
1
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
Published in International journal of molecular sciences (30-12-2022)“…CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in multiple myeloma (MM), making them ideal therapeutic…”
Get full text
Journal Article -
2
Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
Published in Cancer medicine (Malden, MA) (01-07-2024)“…Background Viral reactivations are frequent in hematologial patients due to their cancer‐related and drug‐induced immunosuppressive status. Daratumumab, an…”
Get full text
Journal Article -
3
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
Published in Frontiers in oncology (15-11-2022)“…Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life…”
Get full text
Journal Article -
4
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
Published in Clinical and experimental medicine (01-12-2023)“…SARS-CoV-2 and its variants cause CoronaVIrus Disease 19 (COVID-19), a pandemic disease. Hematological malignancies increase susceptibility to severe COVID-19…”
Get full text
Journal Article -
5
-
6
P1544: IMPACT OF SARS‐COV 2 INFECTION, IN TREATED NHL‐B AND HD, AFTER VACCINATION AND PREVENTIVE THERAPY WITH ANTIBODIES: OUR EXPERIENCE
Published in HemaSphere (08-08-2023)Get full text
Journal Article -
7
Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
Published in Biomedicines (10-07-2022)“…The serum free light-chain (FLC) ratio is a sensitive tool for the differential diagnosis of plasma cell disorders and is biomarker of multiple myeloma (MM)…”
Get full text
Journal Article -
8
Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
Published in Open medicine (Warsaw, Poland) (21-04-2021)“…Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality,…”
Get full text
Journal Article -
9
-
10
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Published in European journal of haematology (06-10-2024)“…Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple…”
Get full text
Journal Article -
11
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
Published in Targeted oncology (01-11-2023)“…Background Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage…”
Get full text
Journal Article -
12
How to Improve the Definition of Chronic Lymphocytic Leukemia Outcome Using a Simple Flow Cytometric Score Based on CD49d and Homing Marker Expression
Published in Blood (02-12-2016)“…The identification of new molecular markers in Chronic Lymphocytic Leukemia (CLL) allowed to better define prognosis and clinical outcome. The actual staging…”
Get full text
Journal Article -
13
Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study
Published in Le infezioni in medicina (01-03-2021)“…Cytomegalovirus (CMV) reactivation is a major cause of morbidity and mortality after organ or hematopoietic stem cell transplantation (HSCT). Letermovir (LTV)…”
Get full text
Journal Article -
14
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials
Published in Hematological oncology (01-07-2024)“…The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety,…”
Get full text
Journal Article -
15
Induction Therapy With Continuous Alternate-Day Low Dose Lenalidomide Combined With Low-Dose Prednisone In Octogenarian Multiple Myeloma Patients
Published in Blood (15-11-2013)“…About 30% of patients with newly diagnosed multiple myeloma (NDMM) are older than 75 years. Immunomodulatory drugs (IMIDs) have improved response rates and…”
Get full text
Journal Article -
16
Cytomegalovirus Reactivation Prophylaxis With Low Dose Valgancyclovir After Hematopoietic Stem Cell Transplantation
Published in Blood (15-11-2013)“…Cytomegalovirus (CMV) reactivation is one of the most frequent complication after hematopoietic stem cell transplantation (HSCT). Pre-transplant CMV-positive…”
Get full text
Journal Article -
17
Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation
Published in Haematologica (Roma) (01-01-1997)“…Division of Hematology, Federico II University Medical School, Naples, Italy. Granulocyte transfusions from G-CSF stimulated donors were added to standard…”
Get full text
Journal Article Conference Proceeding -
18
Danazol for myelodysplastic syndromes
Published in British journal of haematology (01-09-1993)Get more information
Journal Article -
19
Central venous catheter insertion: a bedside procedure for haematological patients
Published in European journal of haematology (01-01-1996)Get more information
Journal Article